Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2020-07-14 Capital/Financing Update
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT THERAPEUTICS AS RAISES NOK 155 MILLION AND LISTS ON OSLO STOCK EXCHANGE’S MERKUR MARKET
Capital/Financing Update Classification · 98% confidence The document announces that EXACT THERAPEUTICS has raised NOK 155 million through a private placement and subsequently listed its shares on the Oslo Stock Exchange's Merkur Market. This activity involves fundraising, capital structure changes (issuing new shares), and a listing event. This aligns directly with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. Although it involves a listing, it is primarily framed as a successful financing round that enabled the listing, making CAP the most precise fit over general regulatory filings (RNS) or delisting (DLST). The document is an announcement, not a comprehensive report like a 10-K or IR.
2020-07-14 Norwegian
EXACT THERAPEUTICS AS RAISES NOK 155 MILLION AND LISTS ON OSLO STOCK EXCHANGE’S MERKUR MARKET
Capital/Financing Update Classification · 98% confidence The document announces that EXACT THERAPEUTICS AS has successfully raised NOK 155 million through a private placement and subsequently listed its shares on the Oslo Stock Exchange’s Merkur Market. This event directly relates to the company's fundraising activities and changes in its capital structure (listing/financing). This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific financing event.
2020-07-14 English
Financial calendar
Report Publication Announcement Classification · 98% confidence The document text is extremely short (266 characters) and explicitly titled 'Financial calendar'. It lists future dates for company events, specifically mentioning '29.04.2021 - Annual Report'. This is not the Annual Report itself (10-K), but rather an announcement about the *timing* of the report's release. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement regarding the publication of a report points towards a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since RPA specifically covers announcements about the timing/release of reports, it is the most appropriate classification.
2020-07-13 English
EXACT Therapeutics AS - Admission Document
Regulatory Filings Classification · 95% confidence The document is explicitly titled an "ADMISSION DOCUMENT" prepared by EXACT Therapeutics AS for its "Admission to trading of shares on Merkur Market." This type of document is required for listing securities on a market venue, detailing the company, the shares being admitted, and associated risks, often serving a function similar to a prospectus or offering circular but tailored to the specific market rules (Merkur Market Admission Rules). Since there is no specific category for an 'Admission Document' or 'Prospectus' among the provided codes, and it is a comprehensive document detailing the company's structure and intent to list, it is best classified as a general regulatory filing or a document related to capital structure/offering, though it is not a standard 10-K, ER, or IR. Given the context of listing/offering securities, 'CAP' (Capital/Financing Update) is a possibility, but 'RNS' (Regulatory Filings) is the most appropriate fallback for non-standard, mandatory regulatory disclosures that don't fit the primary financial report categories (10-K, IR, ER). However, because this document is fundamentally about the issuance and admission of shares, it strongly relates to capital structure changes. Since it is a formal document detailing the terms of the share admission, it is closer to a financing/capital event than a general regulatory announcement. Given the options, and recognizing this is a document related to the initial public offering/listing process, 'CAP' (Capital/Financing Update) is a strong candidate, but 'RNS' is the safest catch-all for non-standard regulatory disclosures. Let's re-evaluate the definitions. This document is not a standard financial report (10-K, IR, ER). It is a document required for listing. If we consider the listing process as a form of capital raising/structuring, 'CAP' fits. If we consider it a mandatory disclosure filing, 'RNS' fits. Since it is a comprehensive document detailing the terms of the security admission, it is a specific type of regulatory disclosure. I will classify it as 'RNS' as it is a specific regulatory filing for admission that doesn't match the other specific financial report types, adhering to the principle that specific financial reports (10-K, IR) take precedence over general filings, and this is not a standard financial report.
2020-07-13 English
EXACT Therapeutics AS - Admission Document
Capital/Financing Update Classification · 95% confidence The document is titled 'EXACT Therapeutics AS - Admission Document' and explicitly states that the attached document is for use in connection with the admission to trading of all issued shares on Merkur Market. This describes the formal documentation required for a listing process, which is a type of financing or capital structure event. While it is a formal document, it is not a standard periodic report (10-K, IR, ER). It is most closely related to the process of raising capital or listing shares. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as an admission document is central to a public offering or listing, which is a financing activity. The document length is short (1293 chars) and it presents the document itself rather than announcing its publication, so RPA/RNS is less likely than the substantive category.
2020-07-13 English
Oslo Børs – EXACT Therapeutics AS - Nytt selskap tas opp til handel på Merkur Market / New company admitted to trading on Merkur Market 14.07.2020
Regulatory Filings Classification · 100% confidence The document is a short announcement from Oslo Børs (the stock exchange) stating that a new company, EXACT Therapeutics AS, is being admitted to trading on the Merkur Market. It provides details like the ticker, ISIN, segment, and the number of shares being listed. This type of announcement, which details the admission of a security to trading, does not fit neatly into the defined categories like 10-K, ER, or DIV. Since it is a general regulatory announcement concerning the listing/trading status of a security, and it is not a specific report, it best fits the general regulatory announcement category, RNS, as a fallback for exchange notices that aren't explicitly covered.
2020-07-13 Norwegian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.